Scholarlink

Background <p>Advanced Merkel cell carcinoma (MCC) has a high response rate to immune checkpoint blockade (ICB). While early phase studies have demonstrated activity of dual ICB with anti-PD-1 plus anti-CTLA-4 agents in both the first- and second-line settings, the role of combination therapy as a first-line approach remains controversial.</p> Methods <p>We conducted a systematic review and meta-analysis to summarize the current evidence of first-line ICB therapy in MCC and to compare the pooled objective response rate (ORR) between combination ICB and monotherapy. Pooled ORRs were estimated using fixed-effects meta-analyses, and these results were statistically compared between combination ICB and monotherapy.</p> <p>In addition to the meta-analysis and as real-world validation, we performed a retrospective chart review of MCC patients treated with first-line combination ICB at a single referral center.</p> Results <p>In the meta-analysis, the pooled ORR of ipilimumab plus nivolumab was significantly higher than that of either anti-PD(L)1 monotherapy when considering all anti-PD-1 and anti-PD-L1 agents (81.0% vs. 49.6%, <i>p</i> = 0.0001) as well as monotherapy when restricted to anti-PD-1 agents (81.0% vs. 57.0%, <i>p</i> = 0.0043). Concordant with pooled trial findings, we identified eight patients treated off protocol with first-line combination ICB at our institution, with seven (87.5%) achieving objective response.</p> Discussion <p>Based on meta-analysis of clinical trial data, first-line treatment of advanced Merkel cell carcinoma with ipilimumab plus nivolumab results in a higher objective response rate compared to monotherapy. The clinical decision to select combination therapy over monotherapy must weigh this response rate benefit with the unknown survival benefit and higher toxicity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月12日

查看全文
  • Tanya Ramadoss,
  • Christian Palacios,
  • Matthew Nichols,
  • Zeynep Eroglu,
  • Joseph Markowitz,
  • Lilit Karapetyan,
  • Ahmad A. Tarhini,
  • Evan J. Wuthrick,
  • Vernon K. Sondak,
  • Kenneth Y. Tsai,
  • Nikhil I. Khushalani,
  • Andrew S. Brohl

摘要

Background

Advanced Merkel cell carcinoma (MCC) has a high response rate to immune checkpoint blockade (ICB). While early phase studies have demonstrated activity of dual ICB with anti-PD-1 plus anti-CTLA-4 agents in both the first- and second-line settings, the role of combination therapy as a first-line approach remains controversial.

Methods

We conducted a systematic review and meta-analysis to summarize the current evidence of first-line ICB therapy in MCC and to compare the pooled objective response rate (ORR) between combination ICB and monotherapy. Pooled ORRs were estimated using fixed-effects meta-analyses, and these results were statistically compared between combination ICB and monotherapy.

In addition to the meta-analysis and as real-world validation, we performed a retrospective chart review of MCC patients treated with first-line combination ICB at a single referral center.

Results

In the meta-analysis, the pooled ORR of ipilimumab plus nivolumab was significantly higher than that of either anti-PD(L)1 monotherapy when considering all anti-PD-1 and anti-PD-L1 agents (81.0% vs. 49.6%, p = 0.0001) as well as monotherapy when restricted to anti-PD-1 agents (81.0% vs. 57.0%, p = 0.0043). Concordant with pooled trial findings, we identified eight patients treated off protocol with first-line combination ICB at our institution, with seven (87.5%) achieving objective response.

Discussion

Based on meta-analysis of clinical trial data, first-line treatment of advanced Merkel cell carcinoma with ipilimumab plus nivolumab results in a higher objective response rate compared to monotherapy. The clinical decision to select combination therapy over monotherapy must weigh this response rate benefit with the unknown survival benefit and higher toxicity.